Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

PHASE4RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

December 15, 2025

Conditions
Coronary Artery Disease
Interventions
DRUG

aspirin plus clopidogrel

After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.

DRUG

prasugrel or ticagrelor

After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.

Trial Locations (1)

32209

RECRUITING

University of Florida, Jacksonville

All Listed Sponsors
lead

University of Florida

OTHER